ANDA Yo-Yo: FDA Receives Second-Lowest Submission Count In October After September Bolus

The rush to submit applications before user fees increased may have motivated the sudden drop, a generic industry trend that continues to grow.

ANDA submissions dropped dramatically from a 140 in September to 14 in October. (Shutterstock)
Key Takeaways
  • The 14 ANDAs submitted in October were the second-lowest monthly total in the GDUFA era.

The aftermath of an ANDA avalanche hit the US Food and Drug Administration in October, even though the actual crush...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Pathways & Standards